PT - JOURNAL ARTICLE AU - Claudio Spick AU - Ken Herrmann AU - Johannes Czernin TI - <sup>18</sup>F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients AID - 10.2967/jnumed.115.158808 DP - 2016 Mar 01 TA - Journal of Nuclear Medicine PG - 420--430 VI - 57 IP - 3 4099 - http://jnm.snmjournals.org/content/57/3/420.short 4100 - http://jnm.snmjournals.org/content/57/3/420.full SO - J Nucl Med2016 Mar 01; 57 AB - 18F-FDG PET/CT has become the reference standard in oncologic imaging against which the performance of other imaging modalities is measured. The promise of PET/MRI includes multiparametric imaging to further improve diagnosis and phenotyping of cancer. Rather than focusing on these capabilities, many investigators have examined whether 18F-FDG PET combined with mostly anatomic MRI improves cancer staging and restaging. After a description of PET/MRI scanner designs and a discussion of technical and operational issues, we review the available literature to determine whether cancer assessments are improved with PET/MRI. The available data show that PET/MRI is feasible and performs as well as PET/CT in most types of cancer. Diagnostic advantages may be achievable in prostate cancer and in bone metastases, whereas disadvantages exist in lung nodule assessments. We conclude that 18F-FDG PET/MRI and PET/CT provide comparable diagnostic information when MRI is used simply to provide the anatomic framework. Thus, PET/MRI could be used in lieu of PET/CT if this approach becomes economically viable and if reasonable workflows can be established. Future studies should explore the multiparametric potential of MRI.